Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 11/20 | 0.76 |
| ▸ | MEN1 | O00255 | 8/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.76 |
| ▸ | NPC1 | O15118 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.76 |
| ▸ | RAB9A | P51151 | 5/20 | 0.76 |
| ▸ | HTT | P42858 | 4/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | USP2 | O75604 | 3/20 | 0.76 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.73 |
| ▸ | ATM | Q13315 | 4/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.64 |
| ▸ | CASP1 | P29466 | 2/20 | 0.64 |
| ▸ | CASP7 | P55210 | 2/20 | 0.64 |
| ▸ | HBB | P68871 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597069 | 0.94 | CYP19A1 (0.70) | CYP19A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13870232 | 0.94 | CYP19A1 (0.73) | CYP19A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13869250 | 0.93 | CYP19A1 (0.86) | CYP19A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13870265 | 0.92 | CYP19A1 (0.71) | CYP19A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13870260 | 0.92 | CYP19A1 (0.71) | CYP19A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL4311784 | 0.92 | CYP19A1 (0.79) | CYP19A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13869303 | 0.92 | CYP19A1 (0.83) | CYP19A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13869330 | 0.91 | CYP19A1 (0.73) | CYP19A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13869279 | 0.91 | CYP19A1 (0.77) | CYP19A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13869300 | 0.91 | CYP19A1 (0.77) | CYP19A1MAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731992-A1 | GREEN ENERGY SOURCES AUTHENTICATION AND COMPLIANCE TESTING | Authentix, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2025042992-A1 | GREEN ENERGY SOURCES AUTHENTICATION AND COMPLIANCE TESTING | AUTHENTIX, INC. (US) | 2025-02-27 | — | — | WO | claimed |
| US-11382868-B2 | Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same | ICURE PHARMACEUTICAL INC. (KR) | 2022-07-12 | — | — | US | claimed |
| CN-107652222-B | Oxime ester photoinitiators | 巴斯夫欧洲公司 | 2021-09-10 | — | — | CN | claimed |
| US-10919909-B2 | Photoinitiated reactions | LINTFIELD LIMITED (GB) | 2021-02-16 | — | — | US | claimed |
| CN-105198793-B | Oxime ester photoinitiators | 巴斯夫欧洲公司 | 2019-08-13 | — | — | CN | claimed |
| US-20190211031-A1 | PHOTOINITIATED REACTIONS | LINTFIELD LIMITED (GB) | 2019-07-11 | — | — | US | claimed |
| US-20190046463-A1 | ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME | ICURE PHARMACEUTICAL INC. (KR) | 2019-02-14 | — | — | US | claimed |
| EP-3415141-A1 | ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME | Icure Pharmaceutical Inc. (KR) | 2018-12-19 | — | — | EP | claimed |
| CN-108697657-A | Ultraviolet-curable hydrogel resin for transdermal administration, hydrogel, and poultice containing same | Icure药品株式会社 | 2018-10-23 | — | — | CN | claimed |
| CN-104284888-B | Oxime ester photoinitiators | 巴斯夫欧洲公司 | 2017-10-27 | — | — | CN | claimed |
| EP-4743828-A1 | PHOTOCURABLE AS WELL AS THERMALLY CURABLE COMPOSITIONS SUITABLE FOR LOW TEMPERATURE CURING | BASF SE (DE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4731992-A1 | GREEN ENERGY SOURCES AUTHENTICATION AND COMPLIANCE TESTING | Authentix, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4006124-B1 | PLASTIC WAVELENGTH CONVERSION FIBER | KURARAY CO (JP) | 2026-01-28 | — | — | EP | disclosed |
| US-20250304727-A1 | PHOTOINITIATOR PACKAGE COMPRISING PHOSPHINE OXIDE PHOTOINITIATORS, COUMARIN-BASED SENSITIZERS AND AMINE ADDITIVES | IGM GROUP B.V. (NL) | 2025-10-02 | — | — | US | disclosed |
| US-20010012596-A1 | For resist applications; thermostability, storage stability | CIBA SPECIALTY CHEMICALS CORP. | 2001-08-09 | — | — | US | disclosed |
| WO-2000052530-A1 | OXIME DERIVATIVES AND THE USE THEREOF AS PHOTOINITIATORS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-09-08 | — | — | WO | disclosed |
| EP-0006271-B2 | WASHING AND SOFTENING COMPOSITIONS CONTAINING NONIONIC BRIGHTENER | THE PROCTER & GAMBLE COMPANY (US) | 1986-01-22 | — | — | EP | disclosed |
| EP-0006271-B1 | WASHING AND SOFTENING COMPOSITIONS CONTAINING NONIONIC BRIGHTENER | THE PROCTER & GAMBLE COMPANY (US) | 1982-03-31 | — | — | EP | disclosed |
| EP-0006271-A1 | Washing and softening compositions containing nonionic brightener | THE PROCTER & GAMBLE COMPANY (US) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919909-B2 | Photoinitiated reactions | KMO, DECR1, PPOX | CYP19A1 22/4885MAPT 1604/4885MEN1 3463/4885 |
| US-20190211031-A1 | PHOTOINITIATED REACTIONS | DOHH, PAH, DBH | CYP19A1 171/4885MAPT 1061/4885MEN1 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.